ESSENTIAL THROMBOCYTHEMIA
Clinical trials for ESSENTIAL THROMBOCYTHEMIA explained in plain language.
Never miss a new study
Get alerted when new ESSENTIAL THROMBOCYTHEMIA trials appear
Sign up with your email to follow new studies for ESSENTIAL THROMBOCYTHEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough blood cancers: adding a targeted drug to chemo
Disease control OngoingThis study is testing whether adding a drug called veliparib to a standard two-drug chemotherapy regimen works better for treating advanced blood cancers. It involves 25 adults with specific types of leukemia and related disorders that have progressed or are hard to treat. Partic…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug tested for stubborn blood cell disorders
Disease control OngoingThis study is testing an experimental drug called IMG-7289 for adults with two rare blood disorders where the body makes too many blood cells. It's for patients whose current standard treatments have stopped working or caused intolerable side effects. The main goal is to see if t…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE2 • Sponsor: Terrence J Bradley, MD • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New Triple-Threat treatment tested for aggressive blood cancers
Disease control OngoingThis study is testing a combination of three drugs—azacitidine, venetoclax, and pevonedistat—for adults newly diagnosed with certain high-risk blood cancers. These include acute myeloid leukemia (AML) that developed from other blood disorders or prior cancer treatment, as well as…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC